Chikungunya vaccine development : progress, problem and opportunity
No Thumbnail Available
Date
2011-01-25
Journal Title
Journal ISSN
Volume Title
Publisher
Journal of the Vector - Borne Diseases
Abstract
Chikungunya (CHIKV) is an arboviral disease transmitted by Aedes mosquitoes. The recent resurgence of CHIKV in Thailand is a matter of great public health concern. Despite the fact that CHIKV resurgence is associated with epidemic, no approved licensed vaccine is currently available. A formalin inactivated CHIKV vaccine revealed absence of untoward reactions or side effects and the acceptable immunogenic response in volunteers attested to the safety and immunogenicity of this vaccine. An attenuated CHIKV virus clone was developed for production of a live vaccine for human use. Vaccine (pilot lot production) elicited safety and immunogenicity of this vaccine in phase I and II studies in healthy adult volunteers. This live vaccine was safe, produced well tolerated side effects, and was highly immunogenic. Among the various vaccine approached, an attenuated live virus to be chosen should contain the gene for a broadly cross reacting protective antigen.
Description
Keywords
Citation
Journal of the Vector - Borne Diseases; Vol. 6 No. 2 July - December 2009; 22-28